Ubs Group Ag Inmune Bio, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 137,315 shares of INMB stock, worth $296,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares

137,315

Previous 136,248 0.78%

Holding current value

$296,600

Previous $636,000 68.55%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$4.93 - $10.48 $5,260 - $11,182	1,067 Added 0.78%	137,315 $1.07 Million
Q4 2024 Feb 14, 2025	BUY	$4.4 - $6.43 $409,604 - $598,581	93,092 Added 215.71%	136,248 $636,000
Q3 2024 Nov 14, 2024	BUY	$4.86 - $9.86 $13,914 - $28,229	2,863 Added 7.11%	43,156 $232,000
Q2 2024 Aug 13, 2024	BUY	$7.15 - $11.84 $14,249 - $23,597	1,993 Added 5.2%	40,293 $355,000
Q1 2024 May 13, 2024	SELL	$10.53 - $14.01 $51,754 - $68,859	-4,915 Reduced 11.37%	38,300 $450,000
Q4 2023 Feb 09, 2024	BUY	$6.6 - $11.52 $9,009 - $15,724	1,365 Added 3.26%	43,215 $486,000
Q3 2023 Nov 09, 2023	SELL	$6.61 - $10.9 $68,744 - $113,360	-10,400 Reduced 19.9%	41,850 $283,000
Q2 2023 Aug 11, 2023	SELL	$6.5 - $10.09 $9,061 - $14,065	-1,394 Reduced 2.6%	52,250 $474,000
Q1 2023 May 12, 2023	BUY	$6.01 - $10.18 $51,770 - $87,690	8,614 Added 19.13%	53,644 $346,000
Q4 2022 Feb 08, 2023	BUY	$6.13 - $7.96 $31,140 - $40,436	5,080 Added 12.72%	45,030 $285,000
Q3 2022 Nov 10, 2022	BUY	$6.04 - $10.44 $6,040 - $10,440	1,000 Added 2.57%	39,950 $248,000
Q2 2022 Aug 10, 2022	BUY	$5.48 - $8.97 $16,440 - $26,910	3,000 Added 8.34%	38,950 $344,000
Q4 2021 Feb 14, 2022	BUY	$9.97 - $20.38 $58,065 - $118,693	5,824 Added 19.33%	35,950 $367,000
Q3 2021 Nov 15, 2021	BUY	$14.13 - $27.85 $320,468 - $631,638	22,680 Added 304.59%	30,126 $585,000
Q2 2021 Aug 13, 2021	BUY	$9.29 - $19.33 $38,432 - $79,968	4,137 Added 125.02%	7,446 $131,000
Q1 2021 May 12, 2021	BUY	$11.61 - $26.85 $35,514 - $82,134	3,059 Added 1223.6%	3,309 $39,000
Q4 2020 Feb 11, 2021	BUY	$7.51 - $17.22 $1,877 - $4,305	250 New	250 $4,000
Q3 2020 Nov 12, 2020	SELL	$4.92 - $15.75 $4,034 - $12,915	-820 Closed	0 $0
Q2 2020 Jul 31, 2020	SELL	$3.1 - $6.09 $957 - $1,881	-309 Reduced 27.37%	820 $4,000
Q1 2020 May 01, 2020	BUY	$2.21 - $6.15 $2,384 - $6,635	1,079 Added 2158.0%	1,129 $4,000
Q4 2019 Feb 14, 2020	SELL	$3.56 - $6.1 $2,264 - $3,879	-636 Reduced 92.71%	50 $0
Q3 2019 Nov 14, 2019	BUY	$5.32 - $10.0 $2,122 - $3,990	399 Added 139.02%	686 $4,000
Q2 2019 Aug 14, 2019	SELL	$7.45 - $11.0 $6,868 - $10,142	-922 Reduced 76.26%	287 $2,000
Q1 2019 May 14, 2019	BUY	$7.08 - $8.2 $8,559 - $9,913	1,209 New	1,209 $9,000

Others Institutions Holding INMB

# of Institutions

Shares Held

6.87M

Call Options Held

202K

Put Options Held

104K

View Full List

About Inmune Bio, Inc.

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $38.8M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

More about INMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account